Verde Science, Inc. (VRCI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerVerde Science, Inc. (VRCI) trades at $0.00002. Verde Science, Inc. is a pharmaceutical research and development company focused on cannabinoid-based prescription medicines. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for VRCI: VRCI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Verde Science, Inc. (VRCI) Healthcare & Pipeline Overview
Verde Science, Inc., a pharmaceutical research and development firm, concentrates on creating cannabinoid-based prescription medicines for a range of medical conditions. Operating in the biotechnology sector, the company seeks to innovate within the pharmaceutical landscape by focusing on cannabinoid research and development, while navigating the complexities of the healthcare industry.
What Is the Investment Thesis for VRCI?
Verde Science, Inc. presents a speculative investment opportunity within the cannabinoid-based pharmaceutical sector. The company's focus on developing prescription medicines for various medical conditions could yield significant returns if its research and development efforts are successful. However, the company's OTC listing and lack of financial data necessitate a cautious approach. Key value drivers include successful clinical trials and regulatory approvals for its cannabinoid-based therapies. Potential catalysts include advancements in cannabinoid research and increasing acceptance of cannabinoid-based medicines within the medical community. Investors should carefully consider the risks associated with investing in a small, OTC-listed pharmaceutical company with limited financial information.
Based on FMP financials and quantitative analysis
VRCI Key Highlights
Verde Science, Inc. focuses on developing cannabinoid-based prescription medicines.
- The company was founded in 2007 and is based in Dallas, Texas.
- Verde Science, Inc. was formerly known as Rango Energy, Inc. and changed its name in May 2014.
- The company trades on the OTC market.
- The company has a negative Beta of -6.16.
Who Are VRCI's Competitors?
VRCI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ELOX Eloxx Pharmaceuticals, Inc. | $15.51 | -1.27% | $53.3M | 33 5-pillar |
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | — |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | — |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | — |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | — |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | — |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | — |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VRCI's Key Strengths?
Focus on cannabinoid-based prescription medicines.
- Potential for innovation in a growing market.
- Experienced management team.
- Established research and development capabilities.
What Are VRCI's Weaknesses?
Limited financial resources.
- OTC listing and associated risks.
- Dependence on regulatory approvals.
- Lack of established commercial infrastructure.
What Are the Key Risks for VRCI?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from established pharmaceutical companies.
- Evolving regulatory landscape.
- Adverse clinical trial results.
- Challenges in securing funding.
- Limited financial resources and OTC listing.
What Are VRCI's Competitive Advantages?
- Proprietary cannabinoid formulations.
- Intellectual property protection through patents.
- Strategic partnerships with research institutions or pharmaceutical companies.
What Does VRCI Do?
Verde Science, Inc., established in 2007 and headquartered in Dallas, Texas, operates as a pharmaceutical research and development company. Originally known as Rango Energy, Inc., the company transitioned to Verde Science, Inc. in May 2014, marking a strategic shift towards the biotechnology sector. The company's core focus is the development of a portfolio of cannabinoid-based prescription medicines designed to address a variety of medical conditions. Verde Science aims to innovate within the pharmaceutical industry by leveraging the potential therapeutic benefits of cannabinoids. The company's research and development efforts are geared towards creating novel treatments for unmet medical needs. While specific details regarding their product pipeline and clinical trial stages are not available, Verde Science is committed to advancing cannabinoid-based therapies through rigorous scientific investigation. The company operates within the broader pharmaceutical and biotechnology landscape, navigating the regulatory and competitive challenges inherent in drug development.
What Products and Services Does VRCI Offer?
- Develops cannabinoid-based prescription medicines.
- Conducts pharmaceutical research and development.
- Focuses on treatments for various medical conditions.
- Aims to innovate within the pharmaceutical industry.
- Seeks to leverage the therapeutic benefits of cannabinoids.
- Navigates the regulatory challenges of drug development.
How Does VRCI Make Money?
- Develops cannabinoid-based prescription medicines.
- Seeks regulatory approvals for its therapies.
- Commercializes its products through partnerships or direct sales.
What Industry Does VRCI Operate In?
Verde Science, Inc. operates within the biotechnology industry, specifically focusing on cannabinoid-based pharmaceuticals. This sector is characterized by rapid innovation, evolving regulations, and increasing interest in the therapeutic potential of cannabinoids. The market for cannabinoid-based medicines is growing, driven by increasing acceptance of medical cannabis and ongoing research into the therapeutic benefits of cannabinoids. However, the industry is also highly competitive, with numerous companies vying to develop and commercialize cannabinoid-based therapies. Verde Science's success will depend on its ability to navigate the regulatory landscape, secure funding for its research and development efforts, and differentiate its products from those of its competitors.
Who Are VRCI's Key Customers?
- Patients with various medical conditions.
- Healthcare providers who prescribe medications.
- Pharmacies that dispense medications.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Verde Science, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dallas, US. The company is led by CEO Harpreet Singh Sangha. VRCI has traded publicly since 2009.
Insider Activity
3 transactions · 3 purchases, 0 sales, 0 other transactions · 1 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Financial Health
Verde Science, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Verde Science, Inc. stands at 401.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
VRCI Financials
VRCI Latest News
No recent news available for VRCI.
VRCI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for VRCI.
Price Targets
Wall Street price target analysis for VRCI.
VRCI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for VRCI; grades run from A+ (80-100) to F (below 30).
Leadership: Harpreet Singh Sangha
CEO
Harpreet Singh Sangha serves as the Chief Executive Officer of Verde Science, Inc. Further research would be required to ascertain his specific expertise and leadership experience within the pharmaceutical or biotechnology sectors.
Track Record: Information regarding Harpreet Singh Sangha's specific achievements and strategic decisions as CEO of Verde Science, Inc. is not available in the provided data. Therefore, it is not possible to assess the company's milestones or performance under his leadership. Further research and access to company reports would be necessary to evaluate his track record and contributions to Verde Science.
VRCI OTC Market Information
The OTC Other tier, where Verde Science trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. This tier is considered the most speculative and carries the highest risk due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or scams.
- Lack of regulatory oversight.
- Verify the company's legal status and registration.
- Research the background and experience of the management team.
- Attempt to obtain audited financial statements.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal disputes.
- Company has been in operation since 2007.
- Focus on pharmaceutical research and development.
- Change of name to reflect a shift in business focus.
- Presence of a CEO.
Common Questions About VRCI (Healthcare)
What do analysts say about VRCI stock?
There is currently no available analyst coverage or consensus on Verde Science, Inc. (VRCI) stock. This lack of analyst coverage is likely due to the company's small market capitalization and OTC listing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on Verde Science, Inc.
- OTC listing and lack of financial disclosure increase investment risk.